类淀粉沉积症药物市场规模、份额和成长分析（按治疗方法、给药途径、适应症、最终用户、通路和地区划分）—2026-2033年产业预测

预计到 2024 年，全球类淀粉沉积症治疗市场规模将达到 228.5 亿美元，到 2025 年将达到 259.8 亿美元，到 2033 年将达到 725.8 亿美元，预测期（2026-2033 年）的复合年增长率为 13.7%。

全球类淀粉沉积症变性治疗市场正经历显着成长，其主要驱动因素包括盛行率上升、公众认知度提高以及临床和诊断能力的进步。新型标靶治疗方法的出现显着提升了安宁疗护的需求，而人口老化加剧了类淀粉沉积症风险，进一步推动了市场扩张。政府的支持性政策，例如孤儿药激励措施，透过经济补贴和加速核准流程，促进了治疗方法的推广应用。此外，医护人员和病患意识提升也有助于早期发现和采用治疗方案。人工智慧和机器学习等先进技术的融合，正在推动药物研发和个人化医疗的发展；物联网和扩增实境正在改善病患监测和介入策略，最终将改变类淀粉沉积症变性治疗的格局。

推动全球类淀粉沉积症药物市场发展的因素

人们对类淀粉沉积症的认识不断提高，诊断能力的提升也推动了该领域治疗药物的需求成长。随着越来越多先前被忽视的罕见疾病病例被确诊，对有效治疗方案的需求日益凸显。此外，先进的治疗调查方法正在促进市场扩张，而医疗报销政策的改善也提高了患者获得诊断和治疗服务的便利性。这些因素共同推动了类淀粉沉积症治疗药物市场的发展，患者和医疗服务提供者都在寻求应对这一复杂健康问题的有效解决方案。

限制全球类淀粉沉积症药物市场的因素

全球类淀粉沉积症变性治疗市场面临许多重大挑战，阻碍了患者接受治疗和产业投资。复杂的药物、特殊的治疗通讯协定以及长期照护带来的高昂费用，可能会使患者望而却步。此外，新药研发（包括RNA治疗方法）带来的巨额资金负担，也可能抑制製药公司在该领域进行创新投入。另外，类淀粉沉积症变性的罕见性和危及生命的性质，以及其潜在的致命后果，进一步阻碍了患者积极寻求和接受现有治疗方案。

类淀粉沉积症治疗市场的全球趋势

全球类淀粉沉积症变性治疗市场正见证着RNA疗法应用显着成长，主要得益于其高效率性和成本效益。患者越来越倾向于选择这类治疗方法，因为它们能够直接针对疾病的根本原因，并以极低的剂量提供长期疗效。此外，研发活动的激增以及生技和製药公司采取的创新策略，也进一步增强了患者对RNA疗法的信心。这种模式转移预示着类淀粉沉积症治疗的未来充满希望，并有望推动相关技术的进步，从而改善患者预后并重塑治疗格局。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术评估
• 监管环境
• 客户和购买标准分析
• 管道分析
• 疾病流行病学

全球类淀粉沉积症药物市场规模（依治疗方法划分）及复合年增长率（2026-2033 年）

• 化疗
• 干细胞移植
• 标靶治疗
• 支持性治疗和手术
• 其他的

全球类淀粉沉积症药物市场规模（按给药途径和复合年增长率划分）（2026-2033 年）

• 口服
• 静脉注射
• 皮下注射

全球类淀粉沉积症药物市场规模（按应用及复合年增长率划分）（2026-2033 年）

• AL类淀粉沉积症
• ATTR类淀粉沉积症
• AA型类淀粉沉积症
• 野生型 ATTR

全球类淀粉沉积症药物市场规模（按最终用户划分）及复合年增长率（2026-2033 年）

• 医院和诊所
• 门诊手术中心
• 居家医疗环境
• 其他的

全球类淀粉沉积症药物市场规模（按分销管道划分）及复合年增长率（2026-2033 年）

• 医院药房
• 零售药房
• 在线的

全球类淀粉沉积症药物市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Pfizer Inc.（USA）
• Alnylam Pharmaceuticals（USA）
• Ionis Pharmaceuticals（USA）
• AstraZeneca（UK）
• Johnson & Johnson（USA）
• Novo Nordisk A/S（Denmark）
• BridgeBio Pharma（USA）
• Prothena Corporation（Ireland）
• Alexion Pharmaceuticals（USA）
• Takeda Pharmaceutical Company（Japan）
• Attralus（USA）
• Caelum Biosciences（USA）
• Zentalis Pharmaceuticals（USA）
• GlaxoSmithKline plc（GSK）（UK）
• Intellia Therapeutics（USA）
• Sanofi（France）
• F. Hoffmann-La Roche（Switzerland）
• Akcea Therapeutics（USA）
• Bristol-Myers Squibb Company（USA）
• Regeneron Pharmaceuticals（USA）

结论与建议

Global Amyloidosis Therapeutics Market size was valued at USD 22.85 Billion in 2024 and is poised to grow from USD 25.98 Billion in 2025 to USD 72.58 Billion by 2033, growing at a CAGR of 13.7% during the forecast period (2026-2033).

The global amyloidosis therapeutics market is experiencing significant growth driven by increasing prevalence, heightened awareness, and advancements in clinical and diagnostic capabilities. The rise of novel and targeted therapies generates substantial demand for palliative care, while an aging population predisposed to amyloidosis further propels market expansion. Supportive government policies, including orphan drug incentives, encourage the uptake of therapies through financial benefits and expedited approval processes. Moreover, heightened awareness among healthcare professionals and patients promotes early detection and adoption of treatment solutions. The integration of advanced technologies such as AI and machine learning enhances drug discovery and personalized medicine, while IoT and augmented reality improve patient monitoring and intervention strategies, ultimately transforming the landscape of amyloidosis therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Amyloidosis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Amyloidosis Therapeutics Market Segments Analysis

Global Amyloidosis Therapeutics Market is segmented by Therapy Type, Route of Administration, Application, End User, Distribution Channel and region. Based on Therapy Type, the market is segmented into Chemotherapy, Stem Cell Transplantation, Targeted Therapy, Supportive Care & Surgery and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on Application, the market is segmented into AL Amyloidosis, ATTR Amyloidosis, AA Amyloidosis and Wild-Type ATTR. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Amyloidosis Therapeutics Market

The growing awareness and improved diagnostic capabilities surrounding amyloidosis are significantly driving the demand for therapeutics in this market. As more individuals are diagnosed with this rare condition-often previously overlooked-the need for effective treatment options is becoming increasingly evident. Additionally, the shift towards advanced treatment methodologies supports market expansion, while enhanced healthcare reimbursement policies facilitate greater access to both diagnostic and therapeutic services. This combination of factors contributes to an escalating interest in the amyloidosis therapeutics market, as patients and healthcare providers seek efficient solutions for this complex health issue.

Restraints in the Global Amyloidosis Therapeutics Market

The global amyloidosis therapeutics market faces several crucial challenges that hinder patient adoption and industry investment. The high expenses associated with advanced medications, specialized treatment protocols, and prolonged care can deter individuals from pursuing necessary therapies. Furthermore, the significant financial burden linked to research and development for new drugs, including RNA-based treatments, may lead pharmaceutical companies to hesitate in committing resources to innovation in this field. Additionally, the rare and life-threatening characteristics of amyloidosis, coupled with its potential fatal outcomes, further contribute to the reluctance of patients to seek out and engage with available therapeutic options.

Market Trends of the Global Amyloidosis Therapeutics Market

The Global Amyloidosis Therapeutics market is witnessing a significant trend towards the rising adoption of RNA-based therapies, driven by their enhanced efficacy and cost-effectiveness. Patients are increasingly favoring these therapies as they directly target the underlying causes of the disease and provide long-term solutions with minimal dosing requirements. Furthermore, the surge in research and development initiatives, coupled with innovative strategies employed by biotech firms and pharmaceutical companies, is bolstering patient confidence in RNA-based treatments. This paradigm shift signifies a promising future for amyloidosis management, fostering advancements that could enhance patient outcomes and reshape therapeutic landscapes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Amyloidosis Therapeutics Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Chemotherapy
• Stem Cell Transplantation
• Targeted Therapy
• Supportive Care & Surgery
• Others

Global Amyloidosis Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Subcutaneous

Global Amyloidosis Therapeutics Market Size by Application & CAGR (2026-2033)

• Market Overview
• AL Amyloidosis
• ATTR Amyloidosis
• AA Amyloidosis
• Wild-Type ATTR

Global Amyloidosis Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Others

Global Amyloidosis Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online

Global Amyloidosis Therapeutics Market Size & CAGR (2026-2033)

• North America (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • US
  • Canada
• Europe (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Attralus (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caelum Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zentalis Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akcea Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations